IL326543A - תרכובת azd5462 לשימוש בטיפול באי ספיקת לב - Google Patents

תרכובת azd5462 לשימוש בטיפול באי ספיקת לב

Info

Publication number
IL326543A
IL326543A IL326543A IL32654326A IL326543A IL 326543 A IL326543 A IL 326543A IL 326543 A IL326543 A IL 326543A IL 32654326 A IL32654326 A IL 32654326A IL 326543 A IL326543 A IL 326543A
Authority
IL
Israel
Prior art keywords
azd5462
compound
treatment
heart failure
heart
Prior art date
Application number
IL326543A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IL326543A publication Critical patent/IL326543A/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL326543A 2023-08-15 2024-08-14 תרכובת azd5462 לשימוש בטיפול באי ספיקת לב IL326543A (he)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202363519654P 2023-08-15 2023-08-15
US202463555454P 2024-02-20 2024-02-20
PCT/EP2024/072857 WO2025036918A1 (en) 2023-08-15 2024-08-14 Compound azd5462 for use in the treatment of heart failure

Publications (1)

Publication Number Publication Date
IL326543A true IL326543A (he) 2026-04-01

Family

ID=92494704

Family Applications (1)

Application Number Title Priority Date Filing Date
IL326543A IL326543A (he) 2023-08-15 2024-08-14 תרכובת azd5462 לשימוש בטיפול באי ספיקת לב

Country Status (6)

Country Link
CN (1) CN121729228A (he)
AU (1) AU2024324579A1 (he)
IL (1) IL326543A (he)
MX (1) MX2026001833A (he)
TW (1) TW202525272A (he)
WO (1) WO2025036918A1 (he)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4259605A1 (en) 2020-12-08 2023-10-18 Astrazeneca AB 4-(2-fluoro-4-methoxy-5-3-(((1-methylcyclobutyl)methyl)carbamoyl)bicyclo[2.2.1]heptan-2-yl)carbamoyl)phenoxy)-1-methylcyclohexane-1-carboxylic acid derivatives and similar compounds as rxfp1 modulators for the treatment of heart failure

Also Published As

Publication number Publication date
WO2025036918A1 (en) 2025-02-20
AU2024324579A1 (en) 2026-04-02
TW202525272A (zh) 2025-07-01
MX2026001833A (es) 2026-04-01
CN121729228A (zh) 2026-03-24

Similar Documents

Publication Publication Date Title
HRP20251568T1 (hr) Omekamtiv mekarbil za liječenje zatajenja srca u odabranim skupinama pacijenata
IL315897A (he) 5-meo-dmt לשימוש בטיפול בהפרעות שינה
IL315901A (he) 5-meo-dmt לשימוש בטיפול בהפרעות שינה
IL285921A (he) פורמולציה תוך-ורידית הכוללת איסטרוקסים לטיפול באי ספיקת לב אקוטית
IL288678A (he) טיפול באי ספיקת לב אצל נבדקים אנושיים
IL280243A (he) תרכובות דומות ל-17בטא-הטרוציקליל-דיגיטליס לטיפול באי-ספיקת לב
GB202011522D0 (en) Neuromodulation for the treatment of circulatory system diseases
IL291412A (he) נגזרות אנדרוסטאן עם פעילות כמגרים טהורים או טהורים לרוב של serca2a לטיפול באי-ספיקת לב
IL326543A (he) תרכובת azd5462 לשימוש בטיפול באי ספיקת לב
GB202205895D0 (en) New medical uses
IL277141A (he) תרכובות לטיפול בפרעות בקצב הלב ואי ספיקת הלב
GB202302225D0 (en) New medical uses
SG10201902000YA (en) Isthmin 1 for treatment of lung inflammation
HK40078461A (en) Treatment of acute heart failure
HK40088920A (en) Methylthioninium compounds for use in the treatment of covid-19
HK40087864A (en) Methylthioninium compounds for use in the treatment of covid-19
AU2024348713A1 (en) Medical device for treating decompensated heart failure
PL4065134T3 (pl) Doustne podawanie bursztynianu żelaza do stosowania w leczeniu niedoboru żelaza u pacjentów z niewydolnością serca
CA3292236A1 (en) Therapeutic agents for heart failure
HK40108887A (en) Methods of reducing the risk of heart failure
EP4326244A4 (en) METHODS TO REDUCE THE RISK OF HEART FAILURE
HK40058355A (en) Istaroxime-containing intravenous formulation for the treatment of acute heart failure (ahf)
HK40109274A (en) Ppar-agonists for use in the treatment of liver failure
GB202217810D0 (en) Medical use
GB202216910D0 (en) Medical use